Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Mitomycin - Generic Drug Details

« Back to Dashboard
Mitomycin is the generic ingredient in four branded drugs marketed by Hospira, Eurohlth Intl Sarl, Bristol Myers, Accord Hlthcare, Bristol, Supergen, and Mobius Therap, and is included in eight NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

This ingredient has eight patent family members in five countries.

There are seven drug master file entries for mitomycin. Three suppliers are listed for this compound.

Summary for Generic Name: mitomycin

Drug Master File Entries: see list7
Suppliers / Packagers: see list3
Bulk Api Vendors: see list52
Clinical Trials: see list68
Patent Applications: see list36,062
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: mitomycin

Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
INJECTABLE;INJECTION050450-002Approved Prior to Jan 1, 1982DISCNNo► subscribe► subscribe
Eurohlth Intl Sarl
INJECTABLE;INJECTION064180-001Dec 23, 1999RXNo► subscribe► subscribe
Eurohlth Intl Sarl
INJECTABLE;INJECTION064117-002Apr 19, 1995RXNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: mitomycin

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2008008802► subscribe
Canada2659314► subscribe
Japan5670546► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.